Revance: Prelim Q4, FY Results and Corporate Update

 

• Preliminary unaudited Q4 RHA® Collection revenue of between $23.0 million and $24.0 million

• Preliminary unaudited cash, cash equivalents, and short-term investments of approximately $225 million as of December 31

• Preliminary unaudited full year GAAP and Non-GAAP operating expenses to be on the low end of or below the previously announced guidance ranges of $375 million to $390 million and $270 million to $285 million, respectively

• Type A Meeting held with FDA regarding DaxibotulinumtoxinA for Injection; Update to be provided upon receipt of meeting minutes

• FDA approved RHA® Redensity dermal filler for the treatment of perioral rhytids (lip lines) on December 22, 2021

https://finance.yahoo.com/news/revance-provides-preliminary-fourth-quarter-130000674.html